Focus:
The European Medicines Agency (EMA) adopted a positive opinion for the combination of Merck’s Keytruda and Pfizer’s Inlyta last month as a first-line treatment for advanced clear-cell renal cell carcinoma
The reimbursement experience with AbbVie’s Orilissa (elagolix) in endometriosis-related pain is likely to spill over to Myovant Sciences’ relugolix, and both drugs’ use to control menstrual bleeding in uterine fibroids
Roche’s risdiplam will find it challenging to wrest market share from Biogen’s approved similar-in-class Spinraza (nusinersen) in spinal muscular atrophy (SMA) due to the latter’s extensive data
Geographical trends shown in prescription patterns and preferences for SCIT and SLIT in the administration of allergen-specific immunotherapy
A significantly high proportion of the population in the West experiences restless leg symptoms, but less than one third receives an accurate diagnosis.
Celgene’s Otezla (apremilast) was approved by the FDA for use in oral ulcers associated with Behcet’s Disease, a rare blood vessel inflammatory disorder
Mistaken as a boil, infection or folliculitis, misdiagnosis in the early stages of Hidradenitis suppurativa leads to delays in diagnosis and treatment.
If approved, Vitrakvi will be the first-in-class tropomyosin receptor kinase (TRK) inhibitor specifically developed to treat tumours that have an NTRK gene fusion and will be the first treatment to...
Baqsimi is the first emergency therapy for treating severe hypoglycemia that is administered without an injection.
Hepatitis B remains a global public health threat, with an estimate of more than 250 million people worldwide living with chronic HBV infections.
